多西他赛联合希罗达治疗转移性乳腺癌的临床观察

目的研究多西他赛联合希罗达治疗转移性乳腺癌的治疗效果和不良反应。方法选取60例转移性乳腺癌患者,随机分为2组,各30例。观察组采用多西他赛联合希罗达治疗,对照组采用多西他赛单药治疗。评价2组患者治疗疗效,记录不良反应。结果观察者总有效率(CR+PR)为60.0%、肿瘤控制率(CR+PR+SD)为86.7%;对照组总有效率(CR+PR)为33.3%、肿瘤控制率(CR+PR+SD)为70.0%;观察组疗效明显高于对照组,差异具有统计学意义(P<0.05);观察组患者常见的不良反应中手足综合征明显少于对照组(χ2=4.6296,P=0.0314),其余指标与对照组比较差异无统计学意义。结论多西他赛联合希罗达治疗转移性乳腺癌比单药治疗效果更佳,值得临床推广。

Objective To study Xeloda combined with docetaxel in metastatic breast cancer therapeutic effect and adverse reactions. Methods 60 patients with metastatic breast cancer patients were randomly divided into two groups, the observation group, 30 patients were treated with Xeloda combined with docetaxel therapy, the control group, more docetaxel monotherapy. Evaluation of efficacy, adverse reactions recorded. Results Observer total efficiency （CR ＋ PR） was 60.0% tumor control rate （CR ＋ PR ＋ SD） was 86.7%, significantly higher overall response rate （CR ＋ PR） 33.3%, tumor control rate （ （CR ＋ PR ＋ SD） 70.0%, a statistically significant difference （P〈0.05）; observation group common adversed reactions in hand-foot syndrome was significantly less than control group （Х^2=4.6296, P=-0.0314）, with the remaining indicators in the control group the difference was not statistically significant. Conclusion Xeloda combined with docetaxel in patients with metastatic breast cancer better, worthy of promotion.